Global fill-finish pharmaceutical contract manufacturing market size is expected to reach $17.1 Bn by 2028 at a rate of 9.3%, segmented as by product type, prefilled syringes, vials, cartridges, other products
This report is a valuable resource that focuses on the challenges faced by the organizations and perspective adopted by key market players to control those threats. It covers main regions of the global market, as well as areas like North America, South America, Asia Pacific, and the rest of the society. Download FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=6345175 Pharmaceutical Aseptic Fill & Finish CMO Market Segment by Type: -Ampoule Filling Services -Vial Filling Services -Prefilled Syringes Filling Services Pharmaceutical Aseptic Fill & Finish CMO Market Segment by Application: -Vaccines -Biologics and Biosimilar -Generics -Patented Small Molecule
The generic injectables market is projected to reach US$ 150.65 billion by 2028 from US$ 74.74 billion in 2021; it is expected to register a CAGR of 10.5% from 2021 to 2028.
The growing prevalence of anaphylaxis and surging aging population are two of the key factors responsible for the growth of the auto-injectors market. The market is predicted to advance at a CAGR of 18.6% during the forecast period (2017–2023). An auto-injector is a medical device used for injecting a particular dose of drugs in patients. Most of the auto-injectors are spring-loaded syringes, designed for the safe dispensation of drugs with ease. Based on product, the auto-injectors market is bifurcated into prefilled and fillable injectors.
According to our new research study on Generic Injectables Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by product type, container type, application, and route of administration,” the generic injectables market size is expected to grow from US$ 74.74 billion in 2021 to US$ 150.65 billion by 2028; it is estimated to grow at a CAGR of 10.5% during 2021–2028. The generic injectables market growth is attributed to low R&D, marketing, and manufacturing costs, and the rising prevalence of chronic illness cases are expected to drive the growth of the market.
... Anticancer drugs Extremely high potency levels and/or toxicity Tumor-targeting formulations Fast-track development programs and high failure rates Small ...